Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 40-47

  Kovaĉević, Ivan ^a   Parojĉić, Jelena ^b   Homŝek, Irena ^c   Tubić Grozdanis, Marija ^d   Langguth, Peter ^d  

^a Medicines and Medical Devices Agency of Serbia Vojvode Stepe   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Galenika Pharmaceuticals   (Serbia)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

BCS; Bioequivalence; Carbamazepine; Gastrointestinal simulation; IVIVC

Indexed keywords

CARBAMAZEPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIMULATION; TABLET; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECT; GASTROINTESTINAL TRACT; METABOLISM; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOLUBILITY;

ADULT; CARBAMAZEPINE; COMPUTER SIMULATION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALE; MODELS, BIOLOGICAL; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TABLETS;

EID: 62649134312     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800128y     Document Type: Article

References (20)

1. FDA/CDER Guidance for industry: Bioavailability and Bioequiva- lence Studies for Orally Administered Drug Products-General Considerations, 2003.
2. EMEA/CPMP Note for guidance on the investigation of bioavail- ability and bioequivalence, 2001.
3. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
4. Martinez, M. N.; Amidon, G. L. A Mechanistic Approach to Understanding the Effects Affecting Drug Absorption: A Review of Fundamentals. J. Clin. Pharmacol. 2002, 42, 620-643.
5. Jantratid, E.; Prekongpans, S.; Amidon, G. L.; Dressman, J. B. Feasibility of of biowaiver extension to biopharmaceutics classification system III drug products: Cimetidine. Clin. Pharma- cokinet. 2006, 45, 385-389.
6. Tubic-Grozdanis, M.; Bolger, M.; Langguth, P. Application of gastrointestinal simulation for extensions of biowaivers of highly permeable compounds. AAPS J. 2008, 10, 213-226.
7. Martindale: The Complete Drug Reference, 2007.
8. FDA/CDER Guidance for industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
9. European Pharmacopoeia, 6th ed.; Council of Europe: Strasbourg Cedex, 2008.
10. Agoram, B.; Woltosz, W. S.; Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavail- ability. Adv. Drug Delivery Rev. 2001, 50 (Suppl. 1), S41-67.
11. Hemenway, J.; Nti-Addae, K.; Guarino, V.; Stella, V. J. Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine. Bioorg. Med. Chem. Lett. 2007, 17, 6629-6632.
12. Summary of Product Characteristics (SPC), Tegretol Tablets 400 mg, Novartis Ireland Limited (revision March 2007). IPHA medicines compendium (www.medicines.ie; access date Jun 21, 2008).
13. Clarke's Analysis of Drugs and Poisons, 3rd ed.; Pharmaceutical Press: London and Chicago, 2004.
14. Dollery, C. Therapeutic Drug, 2nd ed.; Churchill: Liverpool, 1999.
15. Lennernas, H.; Knutson, L.; Knutson, T.; Lesko, L.; Salmonson, T.; Amidon, G. L. Human effective permeability data for atenolol, metoprolol, propranolol, desipramine and carbamazepine to be used in the proposed biopharmaceutical classification for IR-products. Eur. J. Pharm. Sci 1996, 4, S69-S71.
16. Kogan, A.; Aserin, A.; Garti, N. Improved solubilization of carbamazepine and structural transitions in nonionic microemul- sions upon aqueous phase dilution. J. Colloid Interface Sci. 2007, 315, 637-647.
17. Kommentar zum Europäischen Arzneibuch; Wissenschaftliche Velagsgeselleschaft: Stuttgart, 2007.
18. Jung, H.; Milan, R. C.; Girard, M. E.; Leon, F.; Montoya, M. A. Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. Int. J. Pharm. 1997, 152, 37-44.
19. Olling, M.; Mensinga, T. T.; Barends, D. M.; Groen, C.; Lake, O. A.; Meulenbelt, J. Bioavailability of carbamazepine from four different products and occurence of side effects. Biopharm. Drug Dispos. 1999, 20, 19-28.
20. The United States Pharmacopoeia 31/National Formulary 24, United States Pharmacopoeia Convention, Rockville, MD, 2008.